Hello again all,
My results from my most recent BMB and PCR were posted to my patient account from MD Anderson today. I've been anxiously waiting for the past 2 weeks for the results, but my oncologist won't be in till next week to go over these results with me.
For a little history, I was diagnosed in April 2013 with WBC at 280,000. I had the initial BMB on April 14th, and was started on Tasigna 300mg twice daily. In May I switched to MD Anderson and they decided to go ahead with another BMB on May 28th. The PCR at this time was still up over 100%, and the BMB showed 12/20 abnormal cells.
So fast forward 3 months and I can't make heads or tails of this new PCR report. Anyone out there that can help to translate this to normal speak?
Procedure Name: MDL Direct: t(9;22) BCR/ABL1 by Real Time PCR
Procedure Date: 08/29/2013
Accession Number: S-13-068321 (M-13-011202)
MATERIALS TESTED
Source material: S-13-068321
Tissue site: Bone marrow
Collection date: 8/29/2013 11:08:00 AM
MOLECULAR RESULTS
t(9;22); BCR-ABL1 Translocation Assay by Quantitative RT-PCR:
A b2a2 BCR-ABL1 fusion transcript coding for the 210kDa BCR-ABL1 fusion protein is detected by quantitative real-time RT-PCR.
The percentage of BCR-ABL1 to ABL1 transcripts is 0.44.
Methodology:
Quantitative real-time PCR analysis was performed on reverse-transcribed RNA from this sample for the BCR-ABL1 fusion transcripts
resulting from the t(9;22)(q34;q11.2) in Leukemia. This multiplex assay is designed to detect common BCR-ABL1 fusion transcripts e13a2
(b2a2), e14a2(b3a2) and e1a2. The fusion transcripts are differentiated based on the size of the PCR product using capillary
electrophoresis. BCR-ABL1 and ABL1 transcript levels are detected simultaneously and quantitative results are expressed as the percent
ratio of BCR-ABL1 to ABL1 transcript levels. This ratio may vary up to one-log because of methodological reasons. The sensitivity of
detection of BCR-ABL1 transcripts by real-time PCR is between 1 in 10,000 and 1 in 100,000.
Comment:
This assay can be used to monitor minimal residual disease (MRD).
ASR Disclaimer:
This test was developed and its performance characteristics determined by the Molecular Diagnostics Laboratory (MDL) at MD Anderson Cancer Center. It has not
been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. This test is
used for clinical purposes. This laboratory is certified under the Clinical Laboratory Improvement Act (CLIA) of 1988 to perform high complexity clinical laboratory
testing.
Entire report and diagnosis completed by: Keyur P Patel MD, PhD 12348 Sep 05, 2013
------END OF REPORT------
Division of Pathology and Laboratory Medicine
U.T.M.D. Anderson Cancer Center
1515 Holcombe Boulevard
Houston, Texas 77030
